Press Releases
Samsung Biologics Plans IPO on KOSPI
Samsung Biologics Plans IPO on KOSPI
- To secure capital for investments as it aims to become a top-tier biopharmaceutical manufacturing company
- Will continue to strengthen its presence in the rapidly growing global biopharmaceutical market
[INCHEON, KOREA] April 28, 2016 - Samsung Biologics on Thursday announced plans for an initial public offering on the KOSPI (Korea Composite Stock Price Index) this year, following a resolution at the Board of Directors.
Through the IPO, Samsung Biologics will be able to secure funds for investments and research into technology innovation as it aims to become a global top-tier biopharmaceutical manufacturing company.
Samsung Biologics will select lead managers for the IPO next month to decide on the exact timing of the listing and the volume of shares to be offered.
"We are pleased with our sustainable expansion through continuous investments and innovation,” said Dr. TH Kim, CEO of Samsung Biologics. "We will continue to strengthen our competitiveness in order to deliver long-term growth and create meaningful value to our customers and shareholders.”
The global biopharmaceutical industry is expected to expand to almost $278 billion by 2020, with an annual growth rate of more than 8% on average, according to a World Preview 2015 report by research firm Evaluate Pharma, amid an aging population and the development of medical technology.
Samsung Biologics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency.
Samsung Biologics is investing a total 850 billion won in its third plant with a capacity of 180,000 liters, which is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation.
Once in operation in 2018, Samsung Biologics is expected to become the world’s largest contract manufacturing organization (CMO) for biologics, with a total production capacity of 360,000 liters.
These materials are not an offer for sale of the securities of Samsung Biologics Co., Ltd. in the United States. The securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. Samsung Biologics Co., Ltd. does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.
Not for distribution in the United States.
Samsung Biologics Plans IPO on KOSPI
- To secure capital for investments as it aims to become a top-tier biopharmaceutical manufacturing company
- Will continue to strengthen its presence in the rapidly growing global biopharmaceutical market
[INCHEON, KOREA] April 28, 2016 - Samsung Biologics on Thursday announced plans for an initial public offering on the KOSPI (Korea Composite Stock Price Index) this year, following a resolution at the Board of Directors.
Through the IPO, Samsung Biologics will be able to secure funds for investments and research into technology innovation as it aims to become a global top-tier biopharmaceutical manufacturing company.
Samsung Biologics will select lead managers for the IPO next month to decide on the exact timing of the listing and the volume of shares to be offered.
"We are pleased with our sustainable expansion through continuous investments and innovation,” said Dr. TH Kim, CEO of Samsung Biologics. "We will continue to strengthen our competitiveness in order to deliver long-term growth and create meaningful value to our customers and shareholders.”
The global biopharmaceutical industry is expected to expand to almost $278 billion by 2020, with an annual growth rate of more than 8% on average, according to a World Preview 2015 report by research firm Evaluate Pharma, amid an aging population and the development of medical technology.
Samsung Biologics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency.
Samsung Biologics is investing a total 850 billion won in its third plant with a capacity of 180,000 liters, which is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation.
Once in operation in 2018, Samsung Biologics is expected to become the world’s largest contract manufacturing organization (CMO) for biologics, with a total production capacity of 360,000 liters.
These materials are not an offer for sale of the securities of Samsung Biologics Co., Ltd. in the United States. The securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. Samsung Biologics Co., Ltd. does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.
Not for distribution in the United States.